Debut Biotechnology's $20M round in August 2025 — backed by L'Oréal BOLD, Fine Structure Ventures, and EDBI — confirmed that AI-driven ingredient discovery is investable infrastructure, not brand R&D. The model: outsourced formulation innovation for brands that cannot afford biotech in-house.